Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Rev Esp Enferm Dig ; 115(5): 261-263, 2023 05.
Article in English | MEDLINE | ID: mdl-35545916

ABSTRACT

Metastases in pancreas are uncommon, ranging from 2 to 5 % of pancreatic malignancies. Choroidal melanoma is rare, and less than 1% spread to the pancreas. It can cause obstructive jaundice if it affects the pancreatic head region. Advanced disease is associated with poor prognosis, however immunotherapy with PD-1 inhibitors (nivolumab or pembrolizumab), alone or in combination with anti-CTLA-4 antibodies (ipilimumab), has shown an increase in survival.


Subject(s)
Melanoma , Humans , Melanoma/drug therapy , Melanoma/pathology , Melanoma/secondary , Ipilimumab , Nivolumab , Pancreas/pathology , Antineoplastic Combined Chemotherapy Protocols
2.
Rev. esp. enferm. dig ; 115(5): 261-263, 2023. ilus
Article in Spanish | IBECS | ID: ibc-220286

ABSTRACT

Las metástasis pancreáticas constituyen sólo el 2-5% de los tumores malignos de éste órgano. El melanoma coroideo es una neoplasia poco común, que en <1% de las ocasiones metastatiza en páncreas, pudiendo ocasionar ictericia obstructiva si afecta a la región de la cabeza pancreática. Las metástasis en este tipo de tumores conllevan mal pronóstico, no obstante la inmunoterapia con inhibidores de PD-1 (nivolumab y pembrolizumab) con o sin anticuerpos anti CTLA-4 (ipilimumab) ha demostrado un aumento de la supervivencia (AU)


Subject(s)
Humans , Male , Middle Aged , Melanoma/diagnostic imaging , Pancreatic Neoplasms/diagnostic imaging , Cholangiopancreatography, Endoscopic Retrograde , Melanoma/drug therapy , Pancreatic Neoplasms/drug therapy , Antineoplastic Agents, Immunological , Magnetic Resonance Imaging , Neoplasm Metastasis , Fatal Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...